Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that its affiliated company has not yet obtained production approval, and the management is progressing with the construction project as per the situation [1] Company Summary - Fu'an Pharmaceutical's affiliated company is currently in the process of obtaining production approval, which has not yet been secured [1] - The management of the company is actively advancing the construction project based on the current circumstances [1]

Group 1 - The company, Fu'an Pharmaceutical (300194), announced on September 26 that it is currently involved in ongoing litigation and will pursue legal avenues to protect its interests [1] - The company's stock price fluctuations are influenced by multiple factors, and it will actively work to maintain its value [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that it has engaged in a series of mergers and acquisitions since its listing, continuously growing and expanding. The company aims to leverage its development platform and enhance management practices to achieve excellent results that satisfy investors [1] Group 1 - The company has conducted a series of mergers and acquisitions since its listing [1] - Fu'an Pharmaceutical is committed to utilizing its development platform effectively [1] - The company aims to improve its management practices to deliver satisfactory results to investors [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that it will disclose all R&D projects entering the registration process in its periodic reports and will provide interim disclosures for significant progress [1] Group 1 - The company will disclose relevant investments and matters that need to be reported through designated media [1]

Core Viewpoint - The company emphasizes its commitment to investor relations management and plans to actively reward investors through cash dividends while conducting market value management within legal and regulatory frameworks [1] Group 1 - The company announced on September 26 that it will continue to enhance its investor relations management efforts [1] - The company intends to actively return value to investors through cash dividends [1] - The company will conduct market value management in a legal and compliant manner [1]

Group 1 - The company announced on September 26 that it will assess the impact of current industry policy changes on its operations [1] - The company will carefully evaluate risks related to construction projects and drug development initiatives [1] - The company plans to prudently advance the progress of its construction projects [1]

证券日报网讯福安药业（300194）9月26日发布公告，在公司回答调研者提问时表示，中期分红主要从 回报投资者考虑。 ...

证券日报网讯 福安药业9月26日发布公告，在公司回答调研者提问时表示，二级市场股票价格波动受多 重因素影响，从公司的角度来讲，将持续做好投资者关系管理，做好生产经营工作，不断改善经营业 绩，积极回报投资者。 （编辑 袁冠琳） ...

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that its intellectual property mainly includes trademarks, utility models, preparation methods, or crystal form patents, but it has not yet obtained valuable composition patents [1] Intellectual Property - The company holds various types of intellectual property, including trademarks and utility models [1] - The focus on preparation methods and crystal form patents indicates a strategic approach to innovation [1] - The absence of valuable composition patents suggests potential areas for future development and investment [1]

Core Viewpoint - The company aims to actively participate in national drug procurement while optimizing its product structure and enhancing its core competitiveness to maintain stable development in response to industry policy changes [1]. Group 1 - The company announced on September 26 that it will respond to industry policy changes [1]. - The company plans to actively engage in national drug procurement [1]. - The company is focused on market expansion and improving its product structure to increase risk resistance [1]. Group 2 - The company aims to enhance its core competitiveness [1]. - The company strives to achieve stable development amidst changing industry dynamics [1].